Filing Flows › Pure Bioscience (PURE) › Q3 FY25
Pure Bioscience (PURE) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Jun 16, 2025
Pure Bioscience (PURE) reported revenue of $489K for the third quarter fiscal 2025 (Q3 FY25), +11% from a year earlier and +25% from the quarter before. Operating margin was -119.4%, net loss $580K (118.6% of revenue).
Pure Bioscience, Q3 FY25: revenue $489K (+11% year over year), operating margin -119.4%, net loss $580K, operating cash flow −$512K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $489K | +25% | +11% |
| Operating profit | −$584K | — | — |
| Net earnings | −$580K | — | — |
| Operating cash flow | −$512K | — | — |
What changed
Revenue was $489K in Q3 FY25, up 11% year over year and up 25% from the previous quarter. PURE Hard Surface was the largest line at 96% of revenue. PURE Hard Surface added $118K year over year (up 34%), 241% of the total change. SILVERION declined 77%.
Gross margin was 57.9%, down 0.8 points from a year earlier. Operating costs exceeded revenue by $584K, an operating margin of -119.4%. Operating expenses fell 19% while revenue rose 11%. The fastest-growing cost line was Research & development (+18%). The quarter ended with a net loss of $580K, narrower than the previous quarter's $798K loss.
Operating cash flow was −$512K. Non-cash charges added back $33K of share-based compensation. Working capital and other items added $35K.
Questions
What was Pure Bioscience's revenue in the third quarter fiscal 2025?
Pure Bioscience (PURE) reported revenue of $489K for the third quarter fiscal 2025 (Q3 FY25), +11% from a year earlier and +25% from the quarter before.
Was Pure Bioscience profitable in the third quarter fiscal 2025?
Operating loss was $584K (-119.4% of revenue) and net loss $580K.
Source: Pure Bioscience 10-Q on SEC EDGAR.